Keyword: Sangamo BioSciences
Two recent advances are focused on using engineered T cells and drug nanocrystals to combat the HIV “reservoirs” that hide in the body and cause the disease to re-emerge.
After deals and acquisitions with Spark Therapeutics and Bamboo, Pfizer is once again looking to bolster its rare and gene therapy pipeline as it outlines a new drug pact with Sangamo.
Gene editing pioneer Sangamo BioSciences has its sights set on curing hemophilia, a rare disorder in which the blood doesn't clot normally.
Sangamo gets a new CEO, Patheon names a president and Nektar expands its executive management. Plus more hirings, firings and retirings throughout the industry.
Big Pharma veteran Dr. Alexander (Sandy) Macrae has taken on the role of president and CEO of Californian biotech Sangamo Biosciences after the retirement of its former head Edward Lanphier.